Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
2023 · The Lancet Oncology · 77 citations
https://doi.org/10.1016/s1470-2045(22)00793-8